Cipla receives South African health authoritys approval for 4-in-1 paediatric ARV formulation

14 Jun 2022 , 06:16 PM

Cipla announced that the South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, 4-in-1 fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. This combination treatment has been developed by Cipla and the not-for-profit Drugs for Neglected Diseases initiative (DNDi). This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades. It does not require refrigeration, has a sweet taste and is easy to administer to infants and children of different weights and ages, a major improvement for both children and their caregivers over previously available formulations. The country has 238,000 children under the age of 15 living with HIV – the highest in the world. Powered by Capital Market – Live News